These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 25127324

  • 1. Evaluation of ototoxicity in patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin and sodium thiosulfate.
    Womack AM, Hayes-Jordan A, Pratihar R, Barringer DA, Hall JH, Gidley PW, Lewin JS.
    Ear Hear; 2014; 35(6):e243-7. PubMed ID: 25127324
    [Abstract] [Full Text] [Related]

  • 2. Ototoxic effects of supradose cisplatin with sodium thiosulfate neutralization in patients with head and neck cancer.
    Madasu R, Ruckenstein MJ, Leake F, Steere E, Robbins KT.
    Arch Otolaryngol Head Neck Surg; 1997 Sep; 123(9):978-81. PubMed ID: 9305250
    [Abstract] [Full Text] [Related]

  • 3. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Freyer DR, Chen L, Krailo MD, Knight K, Villaluna D, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen ML, Wiernikowski J, Neuwelt EA, Sung L.
    Lancet Oncol; 2017 Jan; 18(1):63-74. PubMed ID: 27914822
    [Abstract] [Full Text] [Related]

  • 4. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Schornagel JH, Dreschler WA, Rasch CR, Balm AJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3759-65. PubMed ID: 17704425
    [Abstract] [Full Text] [Related]

  • 5. Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients.
    Viglietta V, Shi F, Hu QY, Ren Y, Keilty J, Wolff H, McCarthy R, Kropp J, Weber P, Soglia J.
    Invest New Drugs; 2020 Oct 20; 38(5):1463-1471. PubMed ID: 32157599
    [Abstract] [Full Text] [Related]

  • 6. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
    Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA.
    N Engl J Med; 2018 Jun 21; 378(25):2376-2385. PubMed ID: 29924955
    [Abstract] [Full Text] [Related]

  • 7. Ototoxic protection of sodium thiosulfate: daily vs constant infusion.
    Stocks RM, Gould HJ, Bush AJ, Dudney BW, Pousson M, Thompson JW.
    Otolaryngol Head Neck Surg; 2004 Jul 21; 131(1):115-9. PubMed ID: 15243567
    [Abstract] [Full Text] [Related]

  • 8. Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin.
    Laplace N, Kepenekian V, Friggeri A, Vassal O, Ranchon F, Rioufol C, Gertych W, Villeneuve L, Glehen O, Bakrin N.
    Int J Hyperthermia; 2020 Jul 21; 37(1):897-902. PubMed ID: 32689832
    [Abstract] [Full Text] [Related]

  • 9. Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients - A retrospective analysis.
    Vachez E, Kefleyesus A, Bakrin N, Ranchon F, Rioufol C, Vassal O, Al-Hadeedi O, Kepenekian V, Glehen O.
    Eur J Surg Oncol; 2024 Feb 21; 50(2):107955. PubMed ID: 38219699
    [Abstract] [Full Text] [Related]

  • 10. A randomized controlled trial to test the efficacy of trans-tympanic injections of a sodium thiosulfate gel to prevent cisplatin-induced ototoxicity in patients with head and neck cancer.
    Rolland V, Meyer F, Guitton MJ, Bussières R, Philippon D, Bairati I, Leclerc M, Côté M.
    J Otolaryngol Head Neck Surg; 2019 Jan 16; 48(1):4. PubMed ID: 30651130
    [Abstract] [Full Text] [Related]

  • 11. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
    Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G.
    Int J Pediatr Otorhinolaryngol; 2001 May 31; 59(1):47-57. PubMed ID: 11376818
    [Abstract] [Full Text] [Related]

  • 12. Round window application of D-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity.
    Wimmer C, Mees K, Stumpf P, Welsch U, Reichel O, Suckfüll M.
    Otol Neurotol; 2004 Jan 31; 25(1):33-40. PubMed ID: 14724489
    [Abstract] [Full Text] [Related]

  • 13. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM, Phillips DS, Fausti SA, Gordon JS, Helt WJ, Wilmington D, Bratt GW, Konrad-Martin D.
    Ear Hear; 2008 Dec 31; 29(6):875-93. PubMed ID: 18753950
    [Abstract] [Full Text] [Related]

  • 14. Toxicity profile of chemotherapy agents used in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Somashekhar SP, Yethadka R, Kumar C R, Ashwin KR, Zaveri S, Rauthan A.
    Eur J Surg Oncol; 2020 Apr 31; 46(4 Pt A):577-581. PubMed ID: 31677939
    [Abstract] [Full Text] [Related]

  • 15. Audiometric patterns in ototoxicity of intra-arterial Cisplatin chemoradiation in patients with locally advanced head and neck cancer.
    Zuur CL, Simis YJ, Lansdaal PE, Rasch CR, Tange RA, Balm AJ, Dreschler WA.
    Audiol Neurootol; 2006 Apr 31; 11(5):318-30. PubMed ID: 16983183
    [Abstract] [Full Text] [Related]

  • 16. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL, Simis YJ, Lansdaal PE, Hart AA, Rasch CR, Schornagel JH, Dreschler WA, Balm AJ.
    Int J Radiat Oncol Biol Phys; 2007 Aug 01; 68(5):1320-5. PubMed ID: 17418969
    [Abstract] [Full Text] [Related]

  • 17. Incidence and associated risk factors for platinum-induced ototoxicity in pediatric patients.
    Waissbluth S, Del Valle Á, Chuang A, Becker A.
    Int J Pediatr Otorhinolaryngol; 2018 Aug 01; 111():174-179. PubMed ID: 29958605
    [Abstract] [Full Text] [Related]

  • 18. Assessment of nephrotoxicity associated with combined cisplatin and mitomycin C usage in laparoscopic hyperthermic intraperitoneal chemotherapy.
    Kapoor R, Robinson KA, Cata JP, Owusu-Agyemang P, Soliz JM, Hernandez M, Mansfield P, Badgwell B.
    Int J Hyperthermia; 2019 Aug 01; 36(1):493-498. PubMed ID: 30935256
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.
    Konrad-Martin D, James KE, Gordon JS, Reavis KM, Phillips DS, Bratt GW, Fausti SA.
    J Am Acad Audiol; 2010 May 01; 21(5):301-14; quiz 357. PubMed ID: 20569665
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC).
    Zeamari S, Floot B, van der Vange N, Stewart FA.
    Anticancer Res; 2003 May 01; 23(2B):1643-8. PubMed ID: 12820435
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.